La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
78 hedge funds and large institutions have $670M invested in La Jolla Pharmaceutical Company in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 25 closing their positions.
508% more call options, than puts
Call options by funds: $5.81M | Put options by funds: $956K
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
18% less funds holding
Funds holding: 95 → 78 (-17)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less capital invested
Capital invested by funds: $891M → $670M (-$221M)
68% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.3M |
| 2 |
BC
Broadfin Capital
New York
|
+$14.6M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$8.77M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.21M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$4.57M |
| 2 |
RI
RTW Investments
New York
|
-$3.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.47M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.31M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$799K |
LJPC Hedge Fund Activity: Q3 2018 in Review
78 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2018, worth a combined $670M — down 25% from $891M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of LJPC and 8 opened new positions — a net loss of 17 holders — while 17 trimmed existing stakes and 35 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $27.3M. The largest seller was Stanley-Laman Group, exiting entirely with an estimated $4.57M sold.
- 78 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2018, down from 95 in Q2 2018.
- Funds reported $670M of La Jolla Pharmaceutical Company stock for Q3 2018, down 25% quarter-over-quarter.
- 8 funds opened new La Jolla Pharmaceutical Company positions in Q3 2018 and 25 closed out, a net change of -17 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q3 2018 was Point72 Asset Management, an estimated $27.3M added.
- The largest La Jolla Pharmaceutical Company seller in Q3 2018 was Stanley-Laman Group, an estimated $4.57M sold.
Based on aggregated 13F filings for Q3 2018.